search
Back to results

Promoting Cognitive Resilience and Reducing Frailty in Older Veterans With Bright Light Therapy (Brite-VET)

Primary Purpose

Veteran Aged 65 and Older

Status
Not yet recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Bright Light Therapy (AYO Glasses)
Bright Light Therapy (AYO Glasses)
Sponsored by
VA Office of Research and Development
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Veteran Aged 65 and Older focused on measuring sleep, aging, veteran, cognition, dementia, functional capacity, frailty

Eligibility Criteria

65 Years - 85 Years (Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Participants studied in this project will include 30 men and 5 women of any race who are community dwellers The investigators seek to recruit relatively healthy individuals that may or may not exhibit early-stage co-morbidities Exclusion Criteria: The investigators will exclude individuals without sleep disturbances (PSQI >5) Are morbidly obese (BMI > 40) Exhibit severe or advanced co-morbidities, or have cognitive impairment

Sites / Locations

  • Kansas City VA Medical Center, Kansas City, MO
  • Kansas City VA Medical Center, Kansas City, MO

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Active Comparator

Arm Label

BLT control

BLT intervention

Arm Description

Bright light glasses that emit a non-therapeutic blue light.

Bright light glasses that emit a more intense therapeutic blue light.

Outcomes

Primary Outcome Measures

Sleep quality
Sleep quality as assessed by Pittsburgh Sleep Quality Index (PSQI). The PSQI contains 19 self-rated questions that combined to form 7 component scores, each with a range of 0 to 3 points. These in turn are added to yield a global score with a range of 0 to 21 points. Higher scores indicate worse sleep quality.
Step counts
Objectively measure activity using FITBIT Charge 5 actigraphy devices. These devices are worn on the wrist and capture total steps.
C-Reactive Protein
Chronic inflammation may be indicative of distress and lead to chronic diseases. The study will examine the change in C-reactive protein in picograms per milliliter in serum from baseline to endpoint at 12 weeks.
Cognitive screen - SLUMS
Cognitive status will be assessed using the VA - St. Louis University Mental Survey (VA-SLUMS) involving memory tests, shape recognition, and story recall. The survey scores range from 0 to 30, with a higher score representing greater cognitive capability.
Quality of life assessment
Change from baseline to endpoint at 12 weeks Quality of life assessment is performed using the Quality of life, enjoyment, and satisfaction questionnaire - short form (Q-LES-Q-SF) survey instrument. The survey instrument scores from 0 to 70 with a greater score representing better quality of life.
Brain Derived Neurotrophic Factor (BDNF)
Serum cognitive marker: change in Brain Derived Neurotrophic Factor (BDNF) in picograms per milliliter from baseline to endpoint after 12 weeks.
Sleep chronotype
Sleep chronotype as assessed by the Morningness/Eveningness survey, which contains 19 self-rated questions with an aggregate score range of 19 to 72.
Sleepiness
Sleepiness as assessed by the Epworth Sleepiness Scale, which contains 8 self-rated questions with an aggregate score range of 0 to 24.
Insomnia
Insomnia as assessed by the Insomnia Severity Index, which contains 7 self-rated questions with an aggregate score range of 0 to 28.
Fatigue
Fatigue as assessed by the Brief Fatigue Inventory, which contains 9 self-rated questions with an aggregate score range of 0 to 90.
Anxiety and depression
Anxiety and depression as assessed by the Hospital Anxiety and Depression Scale (HADS), which contains 14 self-rated questions with an aggregate score range of 0 to 21. Higher scores indicate greater anxiety and depression.
Sleep disorders
Sleep disorders as assessed by the Holland Sleep Disorders Questionnaire, which contains 32 self-rated questions with an aggregate score range of 32 and 160. Higher scores indicate more sleep disorders.
Sleep quantity
Objectively measure sleep quantity using FITBIT Charge 5 devices. These devices are worn on the wrist and can measure total sleep time.
Interleukin-6
Chronic inflammation may be indicative of distress and lead to chronic diseases. The study will examine the change in interleukin-6 in picograms per milliliter in serum from baseline to endpoint at 12 weeks.
Interleukin-10
Chronic inflammation may be indicative of distress and lead to chronic diseases. The study will examine the change in interleukin-10 in picograms per milliliter in serum from baseline to endpoint at 12 weeks.
Amyloid beta 42/40 ratio
Serum cognitive marker: change in amyloid beta 42/40 ratio (a unitless measure derived from the ratio of serum amyloid-beta 42 in picograms per milliliter divided by serum amyloid-beta 40 in picograms per milliliter) from baseline to endpoint after 12 weeks.
Phosphorylated tau (P-tau)
Serum cognitive marker: plasma levels of phosphorylated tau (P-tau) in picograms per milliliter from baseline to endpoint after 12 weeks.
Cognitive screen - Cognivue
Cognivue to assess cognition. This is a computer based combinatorial visual and reaction time test, which is scored 0 to 100. Higher scores indicate better cognitive performance.
Sleep stages
Objectively measure duration of sleep stages using FITBIT Charge 5 devices. These devices are worn on the wrist and assess time spent in light, deep, and REM sleep stages.

Secondary Outcome Measures

Short Physical Performance Battery
The Short physical performance battery (SPPB) is a battery of test often used in geriatric research to capture functional capacity in older adults. The test includes a balance and coordination assessment via asking participants to hold stances with three different foot positions (side-by-side, semi-tandem, and tandem: score 0-4), a gait speed test of approximately 10 feet (score 0-4 based on time), and a chair rise timed test where a participant is asked to rise from a chair 5 times (score 0-4 based on time). The composite score is therefore 0 to 12. Higher scores indicate better performance.
Frailty assessment
Frailty is a syndrome marked by greater susceptibility to adverse outcomes like falls and disability. We will be using the Fried Frailty Phenotype that includes: 1) unexpected weight loss of 5% or more in the last year or BMI < 18.5; score 0 or 1 if positive, 2) grip strength with BMI dependent cut points for men and women; score 0 or 1 if positive, 3) gait speed with height and sex dependent cutoffs; score 0 or 1 if positive, 4) activity assessed by a survey of the frequency of mild/moderate/energetic physical activity; score of 0 or 1, the latter if positive for hardly ever or never engaging in moderate or energetic physical activity, and 5) endurance assessed by survey of bed rest during the day; score of 0 or 1, the latter if occurring every day or every week. The composite score is therefore 0 to 5. Higher scores indicate more frailty.
Gait speed
Participants are asked to perform a timed walk of approximately 15 feet in length.
Muscle strength
Change from baseline to endpoint at 12 weeks Leg and arm strength will be measured using a small handheld dynamometer where the device is placed on the wrist or ankle as the participant is asked to extend or contract the limb with full force.
Body Composition (Lean and fat mass)
Body composition will be measured using bioelectric impedance (BIA) - a technique where participants are asked to stand on the measurement device and hold on to two metal handles. A light - and non-detectable - current is then transmitted allowing for collection of body fat and lean mass in the subject. The assessment takes roughly 2-3 minutes.

Full Information

First Posted
August 9, 2022
Last Updated
October 6, 2023
Sponsor
VA Office of Research and Development
search

1. Study Identification

Unique Protocol Identification Number
NCT05631236
Brief Title
Promoting Cognitive Resilience and Reducing Frailty in Older Veterans With Bright Light Therapy
Acronym
Brite-VET
Official Title
Promoting Cognitive Resilience and Reducing Frailty in Older Veterans With Bright Light Therapy
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
November 1, 2023 (Anticipated)
Primary Completion Date
December 31, 2024 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
VA Office of Research and Development

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Frailty is a multifactorial syndrome characterized by vulnerability to stressors that is intricately linked to cognitive impairment and mortality risk. Bright light therapy (BLT) reduces circadian disturbances by resynchronizing the hypothalamic biological clock via specific wavelengths of light. Human trials have demonstrated that BLT improves sleep quality and cognitive function in older adults. However, BLT has not been examined for use in older Veteran populations, particularly the impact on frailty. This randomized trial will assess the feasibility of employing BLT to study impacts on frailty, cognition, and sleep in older Veterans. Findings from this pilot will establish the power and effect size necessary for larger trials to support the use of BLT as readily available home-based treatment to improve healthspan of Veterans.
Detailed Description
Promoting cognition and reducing frailty in older Veterans with bright light therapy Frailty is a multifactorial syndrome characterized by vulnerability to stressors that increases disability and mortality risk. Thirty percent of Veterans 65 years or older are frail, which is three-times higher than aged matched non-Veterans. Frailty is intricately linked with cognitive impairment and Veterans are particularly susceptible with 14 percent exhibiting cognitive decline, some with early onset as young as 45 years of age. Importantly, 70% of frail and cognitively impaired older adults exhibit sleep disturbances, which makes identifying and improving sleep quality an attractive therapeutic strategy to enhance healthspan. Furthermore, this is of special interest as 55% of older Veterans experience sleep disturbances. The goal of this study is to examine the feasibility of utilizing bright light therapy (BLT) as a strategy to improve sleep via reduction of circadian rhythm disturbances. The long-term goal is to assess the potential for improving cognition and reducing frailty in older Veterans. BLT works by resynchronizing the hypothalamic biological clock via brief exposure to specific wavelengths of light following awakening, which restores melatonin and circadian rhythms. However, BLT has not been examined for reducing frailty in older Veteran populations. This project will therefore lay the foundation for larger trials the evaluate BLT in the treatment and prevention of cognitive disorders and to promote healthy aging.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Veteran Aged 65 and Older
Keywords
sleep, aging, veteran, cognition, dementia, functional capacity, frailty

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized placebo control trial.
Masking
Participant
Masking Description
Bright light therapy devices include two sets: intervention that emit blue light and the control that emits light at a non-therapeutic intensity.
Allocation
Randomized
Enrollment
35 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
BLT control
Arm Type
Placebo Comparator
Arm Description
Bright light glasses that emit a non-therapeutic blue light.
Arm Title
BLT intervention
Arm Type
Active Comparator
Arm Description
Bright light glasses that emit a more intense therapeutic blue light.
Intervention Type
Device
Intervention Name(s)
Bright Light Therapy (AYO Glasses)
Intervention Description
Bright light glasses that emit a more intense therapeutic blue light.
Intervention Type
Device
Intervention Name(s)
Bright Light Therapy (AYO Glasses)
Intervention Description
Bright light glasses that emit a non-therapeutic blue light.
Primary Outcome Measure Information:
Title
Sleep quality
Description
Sleep quality as assessed by Pittsburgh Sleep Quality Index (PSQI). The PSQI contains 19 self-rated questions that combined to form 7 component scores, each with a range of 0 to 3 points. These in turn are added to yield a global score with a range of 0 to 21 points. Higher scores indicate worse sleep quality.
Time Frame
Change from baseline to endpoint at 12 weeks
Title
Step counts
Description
Objectively measure activity using FITBIT Charge 5 actigraphy devices. These devices are worn on the wrist and capture total steps.
Time Frame
Change from baseline to endpoint at 12 weeks
Title
C-Reactive Protein
Description
Chronic inflammation may be indicative of distress and lead to chronic diseases. The study will examine the change in C-reactive protein in picograms per milliliter in serum from baseline to endpoint at 12 weeks.
Time Frame
Change from baseline to endpoint at 12 weeks
Title
Cognitive screen - SLUMS
Description
Cognitive status will be assessed using the VA - St. Louis University Mental Survey (VA-SLUMS) involving memory tests, shape recognition, and story recall. The survey scores range from 0 to 30, with a higher score representing greater cognitive capability.
Time Frame
Change from baseline to endpoint at 12 weeks
Title
Quality of life assessment
Description
Change from baseline to endpoint at 12 weeks Quality of life assessment is performed using the Quality of life, enjoyment, and satisfaction questionnaire - short form (Q-LES-Q-SF) survey instrument. The survey instrument scores from 0 to 70 with a greater score representing better quality of life.
Time Frame
Change from baseline to endpoint at 12 weeks
Title
Brain Derived Neurotrophic Factor (BDNF)
Description
Serum cognitive marker: change in Brain Derived Neurotrophic Factor (BDNF) in picograms per milliliter from baseline to endpoint after 12 weeks.
Time Frame
Change from baseline to endpoint at 12 weeks
Title
Sleep chronotype
Description
Sleep chronotype as assessed by the Morningness/Eveningness survey, which contains 19 self-rated questions with an aggregate score range of 19 to 72.
Time Frame
Change from baseline at 12 weeks
Title
Sleepiness
Description
Sleepiness as assessed by the Epworth Sleepiness Scale, which contains 8 self-rated questions with an aggregate score range of 0 to 24.
Time Frame
Change from baseline at 12 weeks
Title
Insomnia
Description
Insomnia as assessed by the Insomnia Severity Index, which contains 7 self-rated questions with an aggregate score range of 0 to 28.
Time Frame
Change from baseline at 12 weeks
Title
Fatigue
Description
Fatigue as assessed by the Brief Fatigue Inventory, which contains 9 self-rated questions with an aggregate score range of 0 to 90.
Time Frame
Change from baseline at 12 weeks
Title
Anxiety and depression
Description
Anxiety and depression as assessed by the Hospital Anxiety and Depression Scale (HADS), which contains 14 self-rated questions with an aggregate score range of 0 to 21. Higher scores indicate greater anxiety and depression.
Time Frame
Change from baseline at 12 weeks
Title
Sleep disorders
Description
Sleep disorders as assessed by the Holland Sleep Disorders Questionnaire, which contains 32 self-rated questions with an aggregate score range of 32 and 160. Higher scores indicate more sleep disorders.
Time Frame
Change from baseline at 12 weeks
Title
Sleep quantity
Description
Objectively measure sleep quantity using FITBIT Charge 5 devices. These devices are worn on the wrist and can measure total sleep time.
Time Frame
Change from baseline at 12 weeks
Title
Interleukin-6
Description
Chronic inflammation may be indicative of distress and lead to chronic diseases. The study will examine the change in interleukin-6 in picograms per milliliter in serum from baseline to endpoint at 12 weeks.
Time Frame
Change from baseline at 12 weeks
Title
Interleukin-10
Description
Chronic inflammation may be indicative of distress and lead to chronic diseases. The study will examine the change in interleukin-10 in picograms per milliliter in serum from baseline to endpoint at 12 weeks.
Time Frame
Change from baseline at 12 weeks
Title
Amyloid beta 42/40 ratio
Description
Serum cognitive marker: change in amyloid beta 42/40 ratio (a unitless measure derived from the ratio of serum amyloid-beta 42 in picograms per milliliter divided by serum amyloid-beta 40 in picograms per milliliter) from baseline to endpoint after 12 weeks.
Time Frame
Change from baseline at 12 weeks
Title
Phosphorylated tau (P-tau)
Description
Serum cognitive marker: plasma levels of phosphorylated tau (P-tau) in picograms per milliliter from baseline to endpoint after 12 weeks.
Time Frame
Change from baseline at 12 weeks
Title
Cognitive screen - Cognivue
Description
Cognivue to assess cognition. This is a computer based combinatorial visual and reaction time test, which is scored 0 to 100. Higher scores indicate better cognitive performance.
Time Frame
Change from baseline at 12 weeks
Title
Sleep stages
Description
Objectively measure duration of sleep stages using FITBIT Charge 5 devices. These devices are worn on the wrist and assess time spent in light, deep, and REM sleep stages.
Time Frame
Change from baseline to endpoint at 12 weeks
Secondary Outcome Measure Information:
Title
Short Physical Performance Battery
Description
The Short physical performance battery (SPPB) is a battery of test often used in geriatric research to capture functional capacity in older adults. The test includes a balance and coordination assessment via asking participants to hold stances with three different foot positions (side-by-side, semi-tandem, and tandem: score 0-4), a gait speed test of approximately 10 feet (score 0-4 based on time), and a chair rise timed test where a participant is asked to rise from a chair 5 times (score 0-4 based on time). The composite score is therefore 0 to 12. Higher scores indicate better performance.
Time Frame
Change from baseline to endpoint at 12 weeks
Title
Frailty assessment
Description
Frailty is a syndrome marked by greater susceptibility to adverse outcomes like falls and disability. We will be using the Fried Frailty Phenotype that includes: 1) unexpected weight loss of 5% or more in the last year or BMI < 18.5; score 0 or 1 if positive, 2) grip strength with BMI dependent cut points for men and women; score 0 or 1 if positive, 3) gait speed with height and sex dependent cutoffs; score 0 or 1 if positive, 4) activity assessed by a survey of the frequency of mild/moderate/energetic physical activity; score of 0 or 1, the latter if positive for hardly ever or never engaging in moderate or energetic physical activity, and 5) endurance assessed by survey of bed rest during the day; score of 0 or 1, the latter if occurring every day or every week. The composite score is therefore 0 to 5. Higher scores indicate more frailty.
Time Frame
Change from baseline to endpoint at 12 weeks
Title
Gait speed
Description
Participants are asked to perform a timed walk of approximately 15 feet in length.
Time Frame
Change from baseline to endpoint at 12 weeks
Title
Muscle strength
Description
Change from baseline to endpoint at 12 weeks Leg and arm strength will be measured using a small handheld dynamometer where the device is placed on the wrist or ankle as the participant is asked to extend or contract the limb with full force.
Time Frame
Change from baseline to endpoint at 12 weeks
Title
Body Composition (Lean and fat mass)
Description
Body composition will be measured using bioelectric impedance (BIA) - a technique where participants are asked to stand on the measurement device and hold on to two metal handles. A light - and non-detectable - current is then transmitted allowing for collection of body fat and lean mass in the subject. The assessment takes roughly 2-3 minutes.
Time Frame
Change from baseline to endpoint at 12 weeks

10. Eligibility

Sex
All
Gender Based
Yes
Gender Eligibility Description
30 men and 5 women
Minimum Age & Unit of Time
65 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Participants studied in this project will include 30 men and 5 women of any race who are community dwellers The investigators seek to recruit relatively healthy individuals that may or may not exhibit early-stage co-morbidities Exclusion Criteria: The investigators will exclude individuals without sleep disturbances (PSQI >5) Are morbidly obese (BMI > 40) Exhibit severe or advanced co-morbidities, or have cognitive impairment
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Kenneth L Seldeen, PhD
Phone
(716) 888-4869
Email
Kenneth.Seldeen@va.gov
First Name & Middle Initial & Last Name or Official Title & Degree
Bruce R Troen, MD
Phone
(816) 922-2755
Email
Bruce.Troen@va.gov
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bruce R. Troen, MD
Organizational Affiliation
Kansas City VA Medical Center, Kansas City, MO
Official's Role
Principal Investigator
Facility Information:
Facility Name
Kansas City VA Medical Center, Kansas City, MO
City
Kansas City
State/Province
Missouri
ZIP/Postal Code
64128-2226
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ramratan R Sharma, PhD MHSA
Phone
816-922-2757
Email
ram.sharma2@va.gov
First Name & Middle Initial & Last Name & Degree
Bruce R. Troen, MD
Facility Name
Kansas City VA Medical Center, Kansas City, MO
City
Kansas City
State/Province
Missouri
ZIP/Postal Code
64128
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bruce R Troen, MD
Phone
716-862-6528
Email
bruce.troen@va.gov
First Name & Middle Initial & Last Name & Degree
Ramratan R Sharma
Phone
?8169222755?
Email
Ram.Sharma2@va.gov

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Final data sets will be made available upon specific request and under an authorized Data Use Agreement. This, in addition to the publications being made available via PubMed Central, will enable validation of results by recipients.
IPD Sharing Time Frame
After analysis and completion of study along with subsequent publication of results.
IPD Sharing Access Criteria
After analysis and completion of study along with subsequent publication of results.

Learn more about this trial

Promoting Cognitive Resilience and Reducing Frailty in Older Veterans With Bright Light Therapy

We'll reach out to this number within 24 hrs